Article

Early-stage prostate Ca is likely to become aggressive, lethal in long term

Even though most early-stage prostate cancers have a slow course, the cancers can become more aggressive and lethal in the long term, according to a study by Swedish researchers (JAMA 2004; 291:2713-9).

Related Videos
Sarah Razavi, MD, answers a question during a Zoom video interview
1 expert in this video
2 experts are featured in this series.
1 expert is featured in this series.
2 experts are featured in this series.
1 expert in this video
1 expert is featured in this series.
1 expert in this video
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Related Content
Woman talking with a doctor | Image Credit: © pucko_ns - stock.adobe.com
May 20th 2025

Experts share insights on next-generation NMIBC therapies

Urology Times staff
A recent Urology Times Clinical Forum provided an in-depth overview of current and emerging strategies for managing NMIBC.
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
May 17th 2025

Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

Amy M. Pearlman, MD Alex Tatem, MD
Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
Urologic surgeons successfully complete world’s first bladder transplant
May 19th 2025

Urologic surgeons successfully complete world’s first bladder transplant

Hannah Clarke
The bladder transplant procedure involved a collaboration between the University of California, Los Angeles and the University of Southern California.
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
SBRT may offer a safe alternative to CFRT after prostatectomy
May 16th 2025

SBRT may offer a safe alternative to CFRT after prostatectomy

Hannah Clarke
Data from the SCIMITAR trial showed that SBRT appeared safe and demonstrated comparable PROs compared with CFRT.
Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI
May 16th 2025

Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI

Melissa Kaufman, MD, PhD, FACS Hannah Clarke
The CELLEBRATE trial is aiming to provide additional evidence to support the safety and efficacy of iltamiocel.
© 2025 MJH Life Sciences

All rights reserved.